Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.49 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4119702 | 0.98 | EPHX1 (0.49) | DRD2CACNA1HEPHX1TDP1CHRM2 | |
| SCHEMBL13075277 | 0.92 | DRD2 (0.56) | DRD2CACNA1HEPHX1TDP1SIGMAR1 | |
| SCHEMBL4024516 | 0.91 | DRD2 (0.56) | DRD2CACNA1HEPHX1TDP1CHRM2 | |
| SCHEMBL485945 | 0.89 | DRD2 (0.55) | DRD2CACNA1HEPHX1TDP1CHRM2 | |
| SCHEMBL7220892 | 0.89 | DRD2 (0.55) | DRD2CACNA1HEPHX1TDP1CHRM2 | |
| SCHEMBL24172673 | 0.87 | DRD2 (0.56) | DRD2CACNA1HEPHX1TDP1SIGMAR1 | |
| SCHEMBL31301250 | 0.87 | DRD2 (0.56) | DRD2CACNA1HEPHX1TDP1SIGMAR1 | |
| SCHEMBL16941149 | 0.87 | MEN1 (0.47) | DRD2CACNA1HEPHX1TDP1SIGMAR1 | |
| SCHEMBL9093109 | 0.87 | CD274 (0.53) | DRD2CACNA1HTDP1 | |
| SCHEMBL31301242 | 0.84 | DRD2 (0.63) | DRD2CACNA1HEPHX1TDP1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118330-A1 | Diurea derivatives | ACTIVE BIOTECH AB (SE) | 2009-05-07 | — | — | US | disclosed |
| US-5561139-A | IMMUNOSUPPRESSANTS; SIDE EFFECT REDUCTION | ABBOTT LABORATORIES (US) | 1996-10-01 | — | — | US | disclosed |
| US-5530120-A | ANALOGS OF ASCOMYCIN AND FK-506 AS IMMUNOSUPPRESSANTS AND-MODULATORS; SIDE EFFECT REDUCTION | ABBOTT LABORATORIES (US) | 1996-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118330-A1 | Diurea derivatives | IL2, CASP2, MAVS | DRD2 1063/4885CACNA1H 2336/4885EPHX1 3766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.